Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 2/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.34 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399210 | 0.96 | LMNA (0.39) | GRM5P2RX7METAP2GRM3MGAT2 | |
| SCHEMBL4397521 | 0.87 | KCNT1 (0.36) | GRM5P2RX7METAP2GRM3LMNA | |
| SCHEMBL4394170 | 0.87 | CYP2C9 (0.37) | P2RX7METAP2SCDCACNA1GCACNA1H | |
| SCHEMBL4392706 | 0.86 | P2RX7 (0.36) | GRM5P2RX7METAP2GRM3SCD | |
| SCHEMBL13953644 | 0.86 | P2RX7 (0.34) | GRM5P2RX7METAP2GRM3LMNA | |
| SCHEMBL4400787 | 0.86 | P2RX7 (0.35) | GRM5P2RX7METAP2GRM3SCD | |
| SCHEMBL14566971 | 0.86 | METAP2 (0.36) | GRM5P2RX7METAP2GRM3SCD | |
| SCHEMBL4397356 | 0.86 | SCD (0.36) | GRM5P2RX7METAP2GRM3SCD | |
| SCHEMBL4398021 | 0.85 | LMNA (0.48) | GRM5METAP2GRM3SCDLMNA | |
| SCHEMBL10077173 | 0.83 | KCNH2 (0.34) | GRM5P2RX7METAP2GRM3SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919921-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-1919921-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7494984-B2 | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-24 | — | — | US | disclosed |
| US-7494984-B2 | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-24 | — | — | US | disclosed |
| US-7494984-B2 | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1919921-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007027754-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027754-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | CCNI, APOBEC3C, CDKN1A | GRM5 4550/4885P2RX7 2374/4885METAP2 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.